Levocabastine
As of the edition of 20 October 2026, Levocabastine is a small molecule: marketed, first approved in 1992 (CH); acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Livostin
- First approved
- 28 February 1992 (CH)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Esteve Pharmaceuticals; 4 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Ear, nose and throat; Immune system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ciba Vision | Earlier holder | 1993 to now |
| Novartis | Acquired holder | 2004 to now |